Microenvironment-driven metabolic adaptations guiding CD8+ T cell anti-tumor immunity

J Park, PC Hsueh, Z Li, PC Ho - Immunity, 2023 - cell.com
The metabolic stress occurring in the tumor microenvironment (TME) hampers T cell anti-
tumor immunity by disturbing T cell metabolic and epigenetic programs. Recent studies are …

Beyond CTLA-4 and PD-1 inhibition: novel immune checkpoint molecules for melanoma treatment

DC Ziogas, C Theocharopoulos, PP Lialios, D Foteinou… - Cancers, 2023 - mdpi.com
Simple Summary Although the incorporation of immune checkpoint inhibitors (ICIs) in
melanoma treatment has significantly improved prognosis for patients with advanced …

[HTML][HTML] Classification of tumor immune microenvironment according to programmed death-ligand 1 expression and immune infiltration predicts response to …

D Sun, J Liu, H Zhou, M Shi, J Sun, S Zhao… - Journal of Thoracic …, 2023 - Elsevier
Introduction According to mechanisms of adaptive immune resistance, tumor immune
microenvironment (TIME) is classified into four types:(1) programmed death-ligand 1 (PD …

Generation of orthotopic patient-derived xenografts in humanized mice for evaluation of emerging targeted therapies and immunotherapy combinations for melanoma

C Yan, CA Nebhan, N Saleh, R Shattuck-Brandt… - Cancers, 2023 - mdpi.com
Simple Summary Patient-derived xenografts (PDX) are valuable models in preclinical
oncology drug development. However, they are not well suited for testing immune-based …

VEGF inhibitors improve survival outcomes in patients with liver metastases across cancer types—A meta-analysis

JW Conway, J Braden, SN Lo, RA Scolyer, MS Carlino… - Cancers, 2023 - mdpi.com
Simple Summary The liver is a common site of metastasis across multiple solid organ
malignancies. Liver metastases are a known site of treatment resistance, regardless of the …

[HTML][HTML] Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer

JY Deng, Q Gou, L Yang, ZH Chen… - … for Immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Background The liver is a frequent site of metastases and liver metastases (LM) correlate
with diminished immunotherapy efficacy in non-small cell lung cancer (NSCLC). This study …

A prognostic nomogram for the cancer-specific survival of white patients with invasive melanoma at BANS sites based on the Surveillance, Epidemiology, and End …

J Huang, H Yu, Y Wan, WK Ming, F Situ, L Zhu… - Frontiers in …, 2023 - frontiersin.org
Objective The purpose of this study was to develop a comprehensive nomogram for the
cancer-specific survival (CSS) of white patients with invasive melanoma at back, posterior …

Gene expressions and high lymphocyte count may predict durable clinical benefits in patients with advanced non-small-cell lung cancer treated with immune …

MT Mouritzen, M Ladekarl, H Hager, TB Mattesen… - Cancers, 2023 - mdpi.com
Simple Summary Despite the promising results not all patients with advanced non-small cell
lung cancer benefit from immunotherapy. Immunotherapy may cause severe adverse …

The microbial metabolite desaminotyrosine enhances T-cell priming and cancer immunotherapy with immune checkpoint inhibitors

L Joachim, S Göttert, A Sax, K Steiger, K Neuhaus… - …, 2023 - thelancet.com
Background Inter-individual differences in response to immune checkpoint inhibitors (ICI)
remain a major challenge in cancer treatment. The composition of the gut microbiome has …

Biofluorescence imaging-guided spatial metabolic tracing: In vivo tracking of metabolic activity in circulating tumor cell-mediated multi-organ metastases

H Luan, S Chen, J Lian, B Zhao, X Xu, Y Chen, Y Yang… - Talanta, 2024 - Elsevier
Circulating tumor cells (CTC) are considered metastatic precursors that are shed from the
primary or metastatic deposits and navigate the bloodstream before undergoing …